OLEA-MEDICAL-SA
13.10.2015 10:01:19 CEST | Business Wire | Press release
October 13, 2015 - Olea Medical SA (“Olea”) announced today that Toshiba Medical Systems Corporation (“Toshiba”) and Olea have completed the acquisition of the outstanding shares of Olea, following approval from the French Ministry of Economy.
This acquisition enables Toshiba to accelerate the growth of its MRI business and offer new clinical added value to healthcare providers by leveraging Olea’s cutting-edge software technology for advanced post-processing and image analysis as well as its broad relationships with the world’s key research institutions and customers.
“This partnership means we will benefit from both Toshiba and Olea’s strengths to accelerate innovation and enhance our global presence”, said Toshio Takiguchi, President and CEO of Toshiba Medical Systems Corporation, “Through the integration of both R&D teams we believe we could bring the innovative solutions and products to play an important role in the development of MRI systems.”
Fayçal Djeridane, President and CEO of Olea Medical SA stated: “This is great news for Olea’s customers and our fabulous team, and we are happy and proud to join the Toshiba family. We are convinced this is the right strategy to pursue our commitment to provide a widely accessible, complete package of simple, safe, fast, and accurate tools for full-body image post processing, in order to help doctors improve the diagnosis and follow-up process for patients’ benefit worldwide.”
Toshiba will also be able to provide the multi-modality solutions by integrating Olea’s post-processing software with “Vitrea”, a widely known enterprise and scanner-connected workstation by Vital Images Inc., another subsidiary of Toshiba, to improve collaboration among experts, consolidate and standardize workflows and enhance diagnostic confidence.
About Olea Medical
Olea Medical™ designs and markets
innovative medical imaging applications that significantly improve
diagnostic processes and treatment evaluation. Created in July 2008,
Olea Medical has continuously increased its portfolio of innovative
vendor-neutral software applications for MRI and CT imaging
post-processing, including emergency settings-dedicated ones. Olea
Medical’s competitive solutions allowing to speed-up and enhance
diagnosis process are now implemented in major health care centers all
over the world, and Olea Medical aims to becoming the leading provider
of safe and accurate medical imaging software. More information at www.olea-medical.com
.
About Toshiba Medical Systems Corporation
Toshiba Medical
Systems Corporation is a leading worldwide provider of medical
diagnostic imaging systems and comprehensive medical solutions, such as
CT, X-ray and vascular, ultrasound, nuclear medicine, and MRI systems,
as well as information systems for medical institutions. Toshiba Medical
Systems Corporation has been providing medical products for over 80
years. Toshiba Medical Systems Corporation is a wholly-owned subsidiary
of Toshiba. Visit Toshiba Medical Systems Corporation's web site at www.toshibamedicalsystems.com/
.
About Toshiba
Toshiba Corporation, a Fortune Global 500
company, channels world-class capabilities in advanced electronic and
electrical product and systems into five strategic business domains:
Energy & Infrastructure, Community Solutions, Healthcare Systems &
Services, Electronic Devices & Components, and Lifestyles Products &
Services. Guided by the principles of The Basic Commitment of the
Toshiba Group, "Committed to People, Committed to the Future", Toshiba
promotes global operations and is contributing to the realization of a
world where generations to come can live better lives.
Founded in
Tokyo in 1875, today's Toshiba is at the heart of a global network of
over 580 consolidated companies employing over 199,000 people worldwide,
with annual sales surpassing 6.6 trillion yen (US$55 billion).
To
find out more about Toshiba, visit www.toshiba.co.jp/index.htm
.
Olea
Medical is a trademark of Olea Medical SA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151013005068/en/
Contact:
Press Contact:
Anca Mitulescu, +33(0)442712420
VP
Clinical Affairs & Marketing
Olea Medical SA
anca.mitulescu@olea-medical.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom